We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Lower Contrast Agent Dose Possible Using 320-Row CT Angiography

By MedImaging International staff writers
Posted on 20 Oct 2011
An analysis of 180-row computed tomography (CT) angiography studies performed using a 320-detector row CT scanner found that a contrast media protocol based on 60 mL of iopamidol,“had sufficient enhancement in more than 96% of coronary segments.”

“Many centers currently use a higher iodine load comparable or equal to 80 ml of iopamidol,” said Frank Rybicki, MD, from Brigham and Women’s Hospital (Boston, MA, USA), and one of the authors of the study. The study revealed, “this is not necessary, and the extra contrast means unnecessary costs and increased risk of contrast-induced nephropathy [CIN] to the patients.”

The risk of CIN is of distinct concern for these patients because they commonly have a renal insufficiency, which is known major risk factor for CIN, Dr. Rybicki added. “We analyzed larger patients only [those with a body mass index of more than 30] and found that 92% of coronary segments had sufficient enhancement,” said Dr. Rybicki. “These results support the general use of 60 mL of iopamidol for CT angiography done on 320-detector row CT scanners,” he said.

The study was published in the October 2011 issue of the American Journal of Roentgenology.

Related Links:

Brigham and Women’s Hospital



Half Apron
Demi
Digital Intelligent Ferromagnetic Detector
Digital Ferromagnetic Detector
Medical Radiographic X-Ray Machine
TR30N HF
Digital Radiography System
DR-300

Channels

Industry News

view channel
Image: MIM KineticID is 510(k)-pending software for dynamic PET imaging and kinetic modeling, enabling time-based radiotracer analysis for clinical and research decisions (Photo courtesy of GE Healthcare)

GE HealthCare Showcases AI-Enabled Nuclear Medicine Portfolio at SNMMI 2026

Nuclear medicine is expanding rapidly as health systems adopt theranostics and broaden access to radiopharmaceuticals, increasing demand for scalable operations and consistent diagnostic confidence.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.